| Literature DB >> 35942383 |
Jianghua Ke1,2, Shuwei Duan1, Linchang Liu1, Zhiwei Yin1, Shuang Li1, Yujing Ke1,2, Jin Yao1,2, Ying Zheng1, Weiguang Zhang1, Yilun Qu1,2, Ping Li1, Zheyi Dong1, Xiangmei Chen1,2.
Abstract
Objective: It is not clear which Traditional Chinese Medicine- (TCM-) related elements affect primary IgA nephropathy (IgAN) progression. Here, we explored the risk factors, based on TCM syndrome elements, related to the prognosis of primary IgAN patients.Entities:
Year: 2022 PMID: 35942383 PMCID: PMC9356779 DOI: 10.1155/2022/2270406
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Flow diagram of the study.
Clinical and pathological characteristics of patients with IgA nephropathy [median (IQR)/n (%)].
| Characteristics | Value ( |
|---|---|
| Baseline | |
| Male (%) | 243 (57.4) |
| Age (years) | 37.0 (30.0–44.0) |
| BMI (kg/m2) | 24.5 (22.0–27.1) |
| MAP (mmHg) | 97.3 (89.3–106.7) |
| Total serum protein (g/L) | 65.5 (60.6–70.3) |
| ALB (g/L) | 39.3 (36.0–42.1) |
| Blood urea nitrogen (mmol/L) | 5.7 (4.5–7.0) |
| SUA (umol/L) | 372.5 (305.6–449.8) |
| Total cholesterol (mmol/L) | 4.3 (3.7–5.0) |
| Triglycerides (mmol/L) | 1.6 (1.1–2.2) |
| HDL-C (mmol/L) | 1.1 (0.9–1.3) |
| LDL-C (mmol/L) | 2.7 (2.3–3.3) |
| Hb (g/L) | 134.0 (119.0–148.0) |
| URBC (HPF) | 9.0 (3.5–22.5) |
| Serum creatinine (umol/L) | 99.5 (77.0–126.0) |
| eGFR (ml/min per 1.73 m2) | 80.6 (57.2–103.0) |
| CKD, | |
| 1 | 160 (37.8) |
| 2 | 145 (34.3) |
| 3a | 64 (15.1) |
| 3b | 37 (8.8) |
| 4 | 17 (4.0) |
| 24 h urinary protein (g/24 h) | 1.2 (0.7–2.0) |
| <0.5, | 54 (12.8) |
| 0.5–1, n (%) | 117 (27.7) |
| 1–2, n (%) | 141 (33.3) |
| 2–3, n (%) | 53 (12.5) |
| ≥3, n (%) | 58 (13.7) |
| Oxford classification (%) | |
| M1 | 185 (43.7) |
| E1 | 84 (19.9) |
| S1 | 310 (73.3) |
| T1 | 116 (27.4) |
| T2 | 81 (19.1) |
| C1 | 114 (27.0) |
| C2 | 5 (1.2) |
| Immunosuppressant use (%) | 231 (54.6) |
| RASB use (%) | 377 (89.1) |
IQR: interquartile range; BMI, body mass index; MAP: mean arterial pressure; ALB: albumin; SUA: serum uric acid; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Hb: hemoglobin; URBC: urine red blood cell count; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; M: mesangial hypercellularity; E: endocapillary hypercellularity; S: segmental glomerulosclerosis or adhesion; T: tubular atrophy/interstitial fibrosis; C: cellular/fibrocellular crescents; and RASB: renin-angiotensin system blocker.
Distribution of syndrome elements in IgAN patients (n (%)).
| Syndrome elements of disease location | Frequency | Syndrome elements of disease nature | Frequency |
|---|---|---|---|
| Kidney | 371 (87.7) | Yin-deficiency | 334 (79.0) |
| Liver | 212 (50.1) | Qi-deficiency | 204 (48.2) |
| Spleen | 154 (36.4) | Dampness | 154 (36.4) |
| Lung | 46 (10.9) | Yang-deficiency | 147 (34.8) |
| Heart | 30 (7.1) | Phlegm | 144 (34.0) |
| Stomach | 10 (2.4) | Blood-deficiency | 136 (32.2) |
| Biao | 8 (1.9) | Blood-stasis | 65 (15.4) |
| Jifu | 7 (1.7) | Heat | 53 (12.5) |
| Water retention | 37 (8.7) | ||
| Qi-depression | 36 (8.5) | ||
| Yang-hyperactivity | 23 (5.4) |
Figure 2Kaplan–Meier analysis for the primary outcome of TCM syndrome elements. (a) Kidney survival rates in the disease location element was liver and nonliver group. (b) Kidney survival rates in the disease location element was spleen and nonspleen group. (c) Kidney survival rates in the disease location element was kidney and non-kidney group. (d) Kidney survival rates in the disease nature element was Qi-deficiency and non-Qi-deficiency group. (e) Kidney survival rates in the disease nature element was Yang-deficiency and non-Yang deficiency group. (f) Kidney survival rates in the disease nature element was phlegm and nonphlegm group. (g) Kidney survival rates in the disease nature element was dampness and nondampness group.
Multivariate Cox proportional hazard regression analysis on the prognosis of IgAN patients.
| Variables | Multivariate cox regression | ||
|---|---|---|---|
| HR | 95% CI |
| |
| Yang-deficiency | 2.338 | 1.208–4.525 | 0.012 |
| Age | 1.006 | 0.967–1.046 | 0.781 |
| MAP | 1.009 | 0.984–1.035 | 0.465 |
| M | 1.200 | 0.625–2.302 | 0.584 |
| E | 0.670 | 0.279–1.607 | 0.369 |
| S | 0.975 | 0.430–2.213 | 0.952 |
| T | — | — | 0.090 |
| T0 | — | — | — |
| T1 | 1.546 | 0.556–4.304 | 0.404 |
| T2 | 2.716 | 1.009–7.316 | 0.048 |
| Immunosuppressant use | 0.643 | 0.325–1.271 | 0.204 |
| RASB use | 1.137 | 0.397–3.257 | 0.812 |
| eGFR | 0.983 | 0.969–0.997 | 0.019 |
| 24 h urinary protein | 1.199 | 1.022–1.407 | 0.026 |
MAP: mean arterial pressure; M: mesangial hypercellularity; E: endocapillary hypercellularity; S: segmental glomerulosclerosis or adhesion; T: tubular atrophy/interstitial fibrosis; RASB: renin-angiotensin system blocker; and eGFR: estimated glomerular filtration rate.
Univariate and multivariate logistic regression analysis of factors associated with Yang-deficiency among IgAN patients.
| Variables | Univariate logistic regression | Multivariate logistic regression | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Female (vs. male) | 3.120 | 2.060–4.725 | <0.001 | 2.419 | 1.483–3.946 | <0.001 |
| Age | 1.041 | 1.018–1.064 | <0.001 | 1.048 | 1.023–1.073 | <0.001 |
| BMI | 0.991 | 0.942–1.043 | 0.729 | |||
| MAP | 0.991 | 0.976–1.006 | 0.257 | |||
| Total serum protein | 0.977 | 0.953–1.002 | 0.070 | |||
| ALB | 0.934 | 0.899–0.970 | <0.001 | |||
| Blood urea nitrogen | 1.006 | 0.938–1.078 | 0.877 | |||
| Serum creatinine | 0.999 | 0.995–1.003 | 0.533 | |||
| SUA | 0.998 | 0.996–1.000 | 0.023 | |||
| Total cholesterol | 1.080 | 0.912–1.280 | 0.373 | |||
| Triglycerides | 0.873 | 0.734–1.037 | 0.123 | |||
| HDL-C | 2.091 | 1.198–3.649 | 0.009 | |||
| LDL-C | 1.175 | 0.933–1.479 | 0.170 | |||
| eGFR | 0.997 | 0.991–1.004 | 0.418 | |||
| Urinary protein | 1.070 | 0.949–1.207 | 0.269 | |||
| Hb | 0.972 | 0.962–0.983 | <0.001 | 0.983 | 0.971–0.996 | 0.011 |
| URBC | 1.019 | 1.007–1.030 | 0.001 | |||
| Immunosuppressant use | 1.170 | 0.782–1.751 | 0.445 | |||
| RASB use | 1.400 | 0.712–2.751 | 0.329 | |||
| M1(vs. M0) | 0.765 | 0.509–1.148 | 0.196 | |||
| E1(vs. E0) | 1.743 | 1.072–2.835 | 0.025 | |||
| S1(vs. S0) | 1.130 | 0.716–1.784 | 0.601 | |||
| T0 | 1.000 | Reference | 0.851 | |||
| T1 | 0.872 | 0.543–1.400 | 0.571 | |||
| T2 | 0.946 | 0.555–1.611 | 0.837 | |||
| C1/C2 (vs. C0) | 1.980 | 1.281–3.061 | 0.002 | 1.845 | 1.154–2.949 | 0.010 |
BMI: body mass index; MAP: mean arterial pressure; ALB: albumin; SUA: serum uric acid; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Hb: hemoglobin; URBC: urine red blood cell count; eGFR: estimated glomerular filtration rate; M: mesangial hypercellularity; E: endocapillary hypercellularity; S: segmental glomerulosclerosis or adhesion; T: tubular atrophy/interstitial fibrosis; C: cellular/fibrocellular crescents; and RASB: renin-angiotensin system blocker.